Follows people with moderate aortic valve disease over time
Studies how moderate narrowing or leaking of the aortic heart valve changes over time.
Plain-language title generated from the registry record
Registry title: Prospective Observational Cohort Study of Moderate Aortic Valve Disease
Key facts
- Where
- Hangzhou, ChinaSee the site
Where in China
- Second Affiliated Hospital of Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Trial code
- NCT06595992
- Record updated
- 19 September 2024
- Original description
The objective of this research is to evaluate and predict the progression of moderate aortic stenosis and regurgitation from clinical characterization, biological, echocardiographic, and computed tomography (CT) et. al. Additionally, try to analyze the potential impact of device or drug therapy on the progression of the conditions.Read full original descriptionShow less
EVOLUTION: Prospective Observational Cohort Study of Moderate Aortic Valve Disease
The objective of this research is to evaluate and predict the progression of moderate aortic stenosis and regurgitation from clinical characterization, biological, echocardiographic, and computed tomography (CT) et. al. Additionally, try to analyze the potential impact of device or drug therapy on the progression of the conditions.
Inclusion: At least 18 years old; Be willing and able to provide informed consent to participate in the study; Patient has moderate aortic valve diseases with echocardiographically derived criteria.
Exclusion: Severe aortic valve diseases with echocardiographically derived criteria or planned cardiac surgery or likely need for surgery within 6 months; Life expectancy is less than 12 months due to non-heart disease (such as cancer, chronic liver disease, chronic kidney disease, or chronic end-stage lung disease, etc.); Severe dementia (cannot sign research informed consent, cannot take care of themselves or complete the study visit); Patients who have undergone elective transfemoral transcatheter aortic valve replacement; Acute pulmonary oedema or cardiogenic shock; The investigator believes that the patient is not suitable to participate in the study or complete the follow-up prescribed by the protocol from other medical, social and psychological aspects; The patient is currently participating in another randomized study.